SomnoMed Limited (ASX:SOM)
Australia
· Delayed Price · Currency is AUD | Market Cap | 141.99M |
| Revenue (ttm) | 118.50M |
| Net Income (ttm) | -2.56M |
| Shares Out | 218.44M |
| EPS (ttm) | -0.01 |
| PE Ratio | n/a |
| Forward PE | 33.68 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 356,367 |
| Average Volume | 57,961 |
| Open | 0.680 |
| Previous Close | 0.675 |
| Day's Range | 0.650 - 0.680 |
| 52-Week Range | 0.370 - 0.945 |
| Beta | 0.94 |
| RSI | 43.74 |
| Earnings Date | Feb 26, 2026 |
About SomnoMed
SomnoMed Limited, together with its subsidiaries, produce and sells devices for the oral treatment of sleep related disorders in the Asia Pacific region, North America, and Europe. It provides SomnoDent Avant, as well as SomnoDent Classic, SomnoDent Flex, and SomnoDent Fusion are offered for the treatment of obstructive sleep apnea. The company also offers SomMorning Repositioner, a product designed to help return patient’s mandible back to its pre-treatment centric position; SomnoBrux splint, a custom fit, acrylic splint for patient’s upper te... [Read more]
Financial Performance
In fiscal year 2025, SomnoMed's revenue was 111.49 million, an increase of 21.65% compared to the previous year's 91.65 million. Losses were -3.46 million, -71.77% less than in 2024.
Financial StatementsNews
SomnoMed Limited (SOMNF) Q2 2026 Earnings Call Transcript
SomnoMed Limited (SOMNF) Q2 2026 Earnings Call Transcript